What Is Norethindrone Acetate? Uses and Side Effects

Norethindrone acetate is a synthetic progestogen, a lab-made relative of the hormone progesterone, prescribed for a range of gynecological conditions including endometriosis, abnormal uterine bleeding, contraception, and menopausal hormone therapy. It was born from one of the more elegant moves in pharmaceutical chemistry: researchers took a testosterone molecule, snipped off a single chemical group, and turned an androgen into a progestogen. That origin story, dating back to 1951, helps explain both the drug’s versatility and some of its quirks, including side effects that trace directly to its testosterone ancestry.

From Testosterone to Progestogen

Norethindrone acetate is the acetate ester of norethindrone (also called norethisterone). The “acetate” part is a small chemical addition that improves absorption when you swallow the pill, but once inside the body, enzymes quickly strip it away. What your cells actually see is norethindrone. This matters because norethindrone acetate on its own has roughly one-tenth the binding affinity for progesterone receptors compared to norethindrone itself, so the drug is essentially a delivery vehicle that converts to its active form after absorption.¹

The drug’s lineage from testosterone is not just a historical curiosity. Norethindrone belongs to the “19-nortestosterone” family of progestins, meaning it was derived by removing the methyl group at the 19th carbon of testosterone. That structural kinship with testosterone gives norethindrone measurable androgenic activity. In lab binding studies, norethindrone acetate binds the androgen receptor with an affinity similar to that of dihydrotestosterone, the body’s most potent natural androgen.² In practice, this androgenic potential is usually mild at standard clinical doses, but it becomes relevant for side effects like acne or unwanted hair growth, which we will get to.

The Ethinyl Estradiol Surprise

One of the less intuitive facts about norethindrone acetate is that your body converts a small fraction of it into ethinyl estradiol, the same synthetic estrogen found in many combined birth control pills. The conversion rate is small, roughly 0.2 to 0.33 percent of the dose, but because norethindrone acetate is sometimes prescribed at higher doses (5 to 15 mg daily for endometriosis, for instance), the resulting ethinyl estradiol levels can become clinically meaningful. In a study measuring blood levels after single doses of 10, 20, and 40 mg, the average peak ethinyl estradiol concentrations were about 58, 178, and 231 pg/mL respectively.³

This conversion has practical consequences. It means norethindrone acetate is not a “pure” progestogen treatment in the way that, say, medroxyprogesterone acetate is. The estrogen component may partly explain why norethindrone acetate helps with hot flashes and bone preservation even when prescribed alone, but it also means the drug carries some estrogen-related risks that would not be expected from a progestogen in isolation. If you have been told to avoid estrogen-containing medications, this is worth discussing with your prescriber.

Endometriosis Pain

One of the most common reasons norethindrone acetate shows up on a prescription pad is endometriosis. By suppressing ovulation and thinning the uterine lining, it quiets the hormonal cycle that fuels endometrial implants outside the uterus. In a study of women with surgically confirmed endometriosis across all stages, starting norethindrone acetate after surgery dropped median pain scores from 5 out of 10 to 0, and bleeding scores fell similarly.⁴ Doses for endometriosis typically start at 5 mg daily and can go higher, which is well above the doses used for contraception.

Norethindrone acetate also fills a specific niche as “add-back therapy” alongside GnRH agonists, drugs that create a temporary menopause-like state to treat severe endometriosis. GnRH agonists alone cause intense hot flashes and bone loss, but adding norethindrone substantially reduced both problems in a prospective trial. Bone mineral density loss at the lumbar spine was significantly less in women who received norethindrone alongside a GnRH agonist, and the loss reversed more completely after treatment ended.⁵ When compared head-to-head with a GnRH agonist used alone, norethindrone acetate avoided the bone density drops seen with the agonist at both the spine and hip over a year of treatment.⁶

Menopausal Hormone Therapy

For women going through menopause who still have a uterus, taking estrogen alone increases the risk of endometrial hyperplasia, an overgrowth of the uterine lining that can progress to cancer. Adding a progestogen counters this risk. Norethindrone acetate paired with estradiol is one of the most widely used combinations for this purpose, available in several branded formulations.

The protective effect is striking. In a year-long trial, women taking estradiol alone developed endometrial hyperplasia at a rate of about 15 percent. Adding continuous norethindrone acetate, even at doses as low as 0.1 mg, cut that rate to under one percent.⁷ This is why the combination regimen is standard for menopausal hormone therapy in women with an intact uterus.

How It Works as a Contraceptive

Norethindrone (without the acetate) is available as a progestogen-only “mini-pill” at a dose of 0.35 mg daily. Norethindrone acetate itself appears in various combined oral contraceptive formulations paired with ethinyl estradiol. The contraceptive mechanism does not rely on any single action but rather stacks several effects together: it suppresses the hormonal surges that trigger ovulation, thickens cervical mucus so sperm cannot easily pass through, and alters the uterine lining to make implantation less likely.⁸

The cervical mucus effect is particularly important for the mini-pill, where ovulation suppression is inconsistent. A pilot study examining cervical mucus changes after norethindrone administration found that mucus quality dropped within two hours of taking the drug and stayed low through 24 hours, while a control condition without progestogen maintained higher mucus scores that would permit sperm penetration.⁹ This thickening effect is why timing matters with the progestogen-only pill; taking it at the same time each day keeps mucus quality consistently hostile to sperm.

Irregular Bleeding and Discontinuation

The single most common complaint with norethindrone acetate is unpredictable bleeding, and it is also the top reason people stop taking it. A retrospective review of adolescents prescribed the drug found a discontinuation rate of about 49 percent, with irregular bleeding cited as the cause in more than half of those who quit.¹⁰ Systemic side effects were the second most common reason for stopping.

The bleeding is not a sign of anything dangerous in most cases. It happens because the progestogen thins and destabilizes the uterine lining, leading to unpredictable spotting or breakthrough bleeding, especially in the first few months. Many women find that the bleeding settles down after three to six months of continuous use. Prescribers often counsel patience through this adjustment period, but for some people the nuisance is simply not tolerable, and switching to a different progestogen or delivery method may help.

Mood and Emotional Well-Being

Mood changes are one of the more frustrating side effects because they can be hard to disentangle from other life circumstances. In the context of menopausal hormone therapy, research suggests that adding norethindrone acetate to estradiol may blunt some of the mood improvements that estrogen alone provides. A long-term study of hormone therapy found that the progestogen component could compromise the beneficial effects of estradiol on emotional well-being and psychosexual functioning.¹¹

This does not mean everyone on norethindrone acetate will feel worse. But if you notice worsening mood, increased irritability, or decreased interest in sex after starting the drug, the progestogen component is worth scrutinizing. Some women do better with a different progestogen or a different delivery method, such as a progestogen-releasing intrauterine device, which provides local endometrial protection with less systemic exposure.

Androgenic Side Effects

Because norethindrone descends structurally from testosterone, it retains some ability to activate androgen receptors. At clinical doses this can show up as oily skin, acne, or in some cases increased facial or body hair. The androgenic binding affinity of norethindrone acetate is in the same range as the body’s most potent androgen, though the effective androgenic dose in living tissue is generally lower than what pure binding studies would suggest.²

For women taking norethindrone acetate specifically to manage acne or hirsutism, this is a mismatch: the drug could theoretically worsen the very symptoms they are trying to treat. Other progestins with less androgenic activity, such as drospirenone or desogestrel, are generally preferred in those situations. If you have been prescribed norethindrone acetate for endometriosis or menstrual management and notice new or worsening acne, the androgenic profile of the drug is the likely explanation.

Effects on Cholesterol

Estrogen therapy generally raises HDL cholesterol and lowers LDL cholesterol, which looks favorable for cardiovascular risk. Adding norethindrone acetate partially offsets the HDL benefit. In a two-year placebo-controlled trial of postmenopausal women, combined estradiol-norethindrone acetate lowered total cholesterol and LDL cholesterol but either left HDL unchanged or reduced it, depending on the regimen. The HDL decrease was driven primarily by the HDL-2 subfraction.¹²

A meta-analysis pooling data from multiple randomized trials confirmed the pattern more precisely: the combination lowered LDL by about 13 mg/dL, total cholesterol by about 19 mg/dL, and triglycerides by about 11 mg/dL, but also lowered HDL by roughly 3.5 mg/dL.¹³ The net effect on actual cardiovascular events remains debated, but the LDL reduction is generally considered the more important marker, and on that front the combination still performs well.

Blood Clot Risk

Venous thromboembolism, meaning deep vein clots or pulmonary embolism, is one of the more serious risks associated with hormonal medications. Norethindrone acetate has traditionally been considered safer in this regard than estrogen-containing pills, but the picture is not quite that simple. A large observational study of reproductive-age women found that higher-dose norethindrone acetate (the 5 mg dose commonly used for endometriosis, not the 0.35 mg mini-pill) was associated with about three times the odds of a venous clot compared to women not using hormonal therapy.¹⁴

The ethinyl estradiol conversion described earlier likely plays a role here. At a 5 mg dose, the small percentage that converts to ethinyl estradiol can produce meaningful circulating estrogen levels, and estrogen is the component most strongly linked to clot risk. This makes the clot risk dose-dependent: the 0.35 mg mini-pill generates negligible ethinyl estradiol and is generally considered safe even for women with clot risk factors, while the 5 mg endometriosis dose is a different story. If you have a personal or strong family history of blood clots, this distinction matters.

Liver Concerns

Norethindrone acetate is metabolized in the liver, and in rare cases it has been associated with liver injury. Case reports have documented elevated liver enzymes, hepatitis-type injury, cholestatic injury, and even benign liver tumors in women taking norethisterone. Women with pre-existing liver disease or chronic kidney disease appear to be at higher risk for these complications.¹⁵ Routine liver function monitoring is not standard practice for most women on the drug, but clinicians generally avoid prescribing it to people with active liver disease, and any unexplained upper abdominal pain, jaundice, or dark urine while taking the medication warrants prompt evaluation.

Drug Interactions and CYP3A4

Once norethindrone acetate is converted to norethindrone in the body, the liver enzyme CYP3A4 handles most of its further breakdown. In laboratory studies, the CYP3A4 inhibitor ketoconazole potently blocked norethindrone metabolism, and a CYP3A4 antibody reduced hydroxylation of norethindrone by 96 percent.¹⁶

In plain terms, drugs that strongly inhibit CYP3A4 can raise norethindrone levels in your blood, potentially intensifying side effects. Common CYP3A4 inhibitors include certain antifungal medications, some HIV protease inhibitors, and grapefruit juice in large amounts. Conversely, drugs that rev up CYP3A4, such as rifampin, certain anti-seizure medications, and St. John’s wort, can speed norethindrone breakdown and reduce its effectiveness. This is especially relevant for contraceptive use, where lower drug levels can mean contraceptive failure. If you are starting or stopping any medication while on norethindrone acetate, flagging the interaction to your pharmacist is a good habit.

Breastfeeding

Progestogen-only formulations, including norethindrone, are generally considered compatible with breastfeeding. The concentrations of progestogen hormones that pass into breast milk are small, and pharmacokinetic reviews have concluded that mothers taking these medications can breastfeed safely.¹⁷ This is one reason the norethindrone mini-pill is often the first-line hormonal contraceptive recommended in the postpartum period. The higher-dose norethindrone acetate formulations used for endometriosis are a different question, since they generate more ethinyl estradiol, and estrogen can suppress milk production. In practice, the 5 mg endometriosis dose is rarely prescribed to women who are actively breastfeeding.

Who Should Think Twice

Most prescribing cautions for norethindrone acetate flow logically from its pharmacology. Because of the ethinyl estradiol conversion at higher doses, women who have contraindications to estrogen, such as a history of estrogen-receptor-positive breast cancer, prior venous thromboembolism, or active liver disease, need careful risk-benefit discussions before taking higher-dose norethindrone acetate. The low-dose mini-pill sidesteps many of these concerns because the estrogen conversion is negligible at 0.35 mg.

Women with migraine with aura are another group where the estrogen conversion matters. Estrogen-containing contraceptives are generally avoided in this population because of an elevated stroke risk, and the fact that higher-dose norethindrone acetate produces measurable ethinyl estradiol complicates what might otherwise seem like a safe progestogen-only option. Again, the mini-pill is typically fine here, but the endometriosis dose is not automatically in the clear.

Smokers over 35 face the same logic. The cardiovascular risks of estrogen-containing hormonal therapy are amplified by smoking, and a drug that quietly converts to ethinyl estradiol is not truly estrogen-free. The magnitude of risk at intermediate doses has not been precisely quantified, which makes prescribing decisions in these populations a judgment call rather than a textbook lookup.